SavedAdd your journal

Journals / Türk Nöroşirürji Dergsi / 2017 / Cilt: 27 - Sayı: 2

Molecular Biology of High Grade Gliomas

Yüksek Gradeli Gliomların Moleküler Biyolojisi

Türker KILIÇ
Timuçin AVŞAR
Pages
162–168
Publication Date
2022-11-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our understanding of high grade glioma biology has increased with the help of molecular technologies.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:For the last several decades the treatment of high grade gliomas has been a field of unknowns and treatment failures, which has created pessimism.
📊
Key Findings & Data:Molecular biological studies in the last decade have significantly improved our understanding of glioma biology.
💡
Conclusion & Impact:Our understanding of high grade glioma biology has increased with the help of molecular technologies.
🔬Design:Review & Systematic Survey
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

For the last several decades the treatment of high grade gliomas has been a field of unknowns and treatment failures, which has created pessimism. The sole reason for this failure was our lack of understanding on tumor biology. Molecular biological studies in the last decade have significantly improved our understanding of glioma biology. Resulting biomarkers have enabled quick and effective classification of the disease. This review will summarize advances on high grade glioma. The World Health Organization (WHO) 2016 classification of gliomas as well as current biomarkers will be summarized. This will be followed by a summary of their place in glioma biology. Molecular markers define different molecular subsets within high grade gliomas and these subsets have unique tumor biologies. Our understanding of high grade glioma biology has increased with the help of molecular technologies.

Özet

Yüksek gradeli tümörlerin tedavisi on yıllardır bilinmezlikler ve başarısızlıklarla dolu bir alan olmuş ve bu hastalığa pessimist bir bakış açısı yaratmıştır. Bu başarısızlığın en önemli nedeni tümör biyolojisini anlayamamış olmamızdır. Son on yıldaki moleküler biyolojik çalışmalar bu heterojen tümör grubunun tümör biyolojisini çok daha iyi anlamamızı sağlamıştır. Bu gelişmeler sonucunda ortaya konan moleküler belirteçler de bugün bu hastalığı etkin ve hızlı bir şekilde sınıflayabilmemizi sağlamıştır. Bu derlemede yüksek gradeli gliomlar konusundaki gelişmeler özetlenecektir. Yüksek gradeli gliomların Dünya Sağlık Örgütü (WHO) 2016 sınıflaması, farklı moleküler belirteçler özetlendikten sonra bunların tümör biyolojisindeki yeri anlatılacaktır. Yüksek gradeli gliomlar konusunda moleküler belirteçler farklı moleküler alt tipleri tanımlar. Bu alt tipler tümör biyolojisi açısından birbirlerinden farklılıklar gösterir. Yüksek gradeli gliomların biyolojisi konusundaki bilgimiz moleküler biyolojik teknikler sayesinde artmıştır.

🔖

Cite This Article

KILIÇ, T., AVŞAR, T. (2022). Molecular Biology of High Grade Gliomas. Türk Nöroşirürji Dergsi, Cilt: 27 - Sayı: 2, 162–168. https://ajindex.com/articles/637400

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Atabay KD, Yildiz MT, Avsar T, Karabay A, Kiliç T: Knockdown of Pin1 leads to reduced angiogenic potential and tumorigenicity in glioblastoma cells. Oncol Lett 10(4): 2385-2389, 2015 2. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN: Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120): 756-760, 2006 3. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, Scheding S, Bengzon J: Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther 17(1): 183-190, 2009 4. Bhujbal SV, de Vos P, Niclou SP: Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors, Adv Drug Deliv Rev 67-68: 142-153, 2014 5. Buckner JC: Factors influencing survival in high-grade gliomas. Semin Oncol 30(6 Suppl 19): 10-14, 2003 6. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network; Noushmehr H, Iavarone A, Verhaak RG: Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3): 550-563, 2016 7. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loeffler JS: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RASdependent manner. Cancer Res 62(15): 4307-4315, 2002 8. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE: Recursive partitioning analysis in three Radiation Therapy Oncology Group (RTOG) malignant glioma trials. J Natl Cancer Inst 85(9): 704-710, 1993 9. DeAngelis L: Brain tumors. N Engl J Med 344: 114-123, 2001 10. Di Vinci A, Casciano I, Marasco E, Banelli B, Ravetti GL, Borzì L, Brigati C, Forlani A, Dorcaratto A, Allemanni G, Zona G, Spaziante R, Gohlke H, Gardin G, Merlo DF, Mantovani V, Romani M: Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: Association with tumor